0
0
In a landmark move, the European Society of Cardiology (ESC) has officially endorsed vaccination as a core strategy to prevent cardiovascular events, positioning it alongside lifestyle modification, medication, and surgical interventions as a foundational pillar of heart disease prevention. This new Clinical Consensus Statement, published in the European Heart Journal on June 3, 2025, reflects a growing body of evidence that respiratory and bacterial infections—including influenza, pneumonia, SARS-CoV-2, and RSV—can significantly worsen heart failure and trigger major adverse cardiovascular events, especially in those with pre-existing heart conditions.
The ESC’s statement reviews extensive clinical data demonstrating that vaccines not only prevent infections but also interrupt inflammatory pathways that lead to cardiac complications. The document highlights that targeted immunization can reduce the risk of heart attacks, strokes, and other serious cardiovascular outcomes, particularly in high-risk groups such as patients with chronic coronary syndromes and heart failure. The consensus aligns with guidelines from both the ESC and the American College of Cardiology/American Heart Association, which recommend vaccination for individuals with chronic heart disease.
Professor Thomas F. Lüscher, ESC President and lead author of the consensus, emphasized, “Vaccination should join lifestyle changes and medications as essential preventive measures.” The statement also addresses rare vaccine-associated myocarditis and provides tailored vaccination schedules for vulnerable populations, including pregnant women and transplant recipients.
Recent research supports these recommendations. A major study involving nearly the entire adult population of England found that the incidence of heart attacks and strokes was lower after COVID-19 vaccination compared to before or without vaccination. The study reported up to a 27% reduction in arterial thromboses after a second dose of the AstraZeneca vaccine and up to a 20% reduction after the Pfizer/BioNTech vaccine. The findings offer reassurance regarding the cardiovascular safety of COVID-19 vaccines and underscore the broader benefits of immunization in reducing cardiovascular risks.
With over 60 million Europeans living with cardiovascular disease and facing heightened risks from respiratory infections, this shift in prevention strategy is expected to have significant public health impacts. Vaccine innovation remains a priority, as new candidates targeting respiratory pathogens are developed to meet the needs of at-risk populations.
Disclaimer: This article is for informational purposes only and does not constitute medical advice. Individuals should consult healthcare professionals for personal recommendations regarding vaccination and cardiovascular health. The information is based on the latest available research and expert consensus as of July 2025, and recommendations may evolve as new evidence emerges.
